| Literature DB >> 21074630 |
Gordon L Phillips1, Steven H Bernstein, Jane L Liesveld, Camille N Abboud, Michael W Becker, Louis S Constine, J J Ifthikharuddin, John E Loughner, Laurie A Milner, David H Vesole, Jonathan W Friedberg.
Abstract
With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November 2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan dose in BEAM could be safely escalated to at least 260 mg/m², a substantial increase from the usual dose of 140 mg/m² in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or dose-limiting toxicity was found. A Phase II trial is planned. 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 21074630 DOI： 10.1016/j.bbmt.2010.11.003
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN： 1083-8791 Impact factor: 5.742